Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Dóra Marosvári"'
Autor:
Csaba Bödör, Endre Sebestyén, Sebastian Brandner, Attila G. Bagó, Béla Kajtár, Beáta Deák, Ádám Nagy, András Matolcsy, Dóra Marosvári, Lilla Reiniger, James Storhoff, Chen N, Hajnalka Rajnai
Central nervous system (CNS) lymphoma is a rare and aggressive non-Hodgkin lymphoma that might arise in the CNS (primary CNS lymphoma, PCNSL) or disseminates from a systemic lymphoma to the CNS (secondary CNS lymphoma, SCNSL). Dysregulated expression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3ee537686f23787364144f4bf10e997
https://doi.org/10.1101/2021.02.05.21249862
https://doi.org/10.1101/2021.02.05.21249862
Autor:
Attila G. Bagó, Noémi Nagy, Dóra Marosvári, Anna Sebestyén, Irén Csala, Csaba Bödör, Zoltan Szallasi, Lilla Reiniger, Csilla Kriston, Melinda Hajdu, Beáta Deák
Publikováno v:
Journal of Neuropathology & Experimental Neurology. 77:268-273
The primary aim of this study was to determine mTOR-pathway activity in primary central nervous system lymphoma (PCNSL), which could be a potential target for therapy. After demonstrating that p-S6 positivity largely exceeded mTOR activity, we aimed
Autor:
Judit Demeter, Béla Kajtár, Tímea Gurbity Pálfi, Zoltán Mátrai, Csaba Bödör, Viktória Fésüs, Péter Farkas, Andras Matolcsy, Dóra Marosvári, Márk Plander, Péter Király, Miklos Egyed
Publikováno v:
Orvosi Hetilap. 158:220-228
Abstract: Introduction: In recent years much progress has been made in the therapy of chronic lymphocytic leukaemia, as the new innovative medicine proved to be effective in managing patients carrying TP53 abnormalities. To identify all these patient
Autor:
Beáta Deák, Bence Bátai, Ning Chen, Dóra Marosvári, Attila G. Bagó, Attila Gyenesei, Bence Galik, Mingdong Liu, Nadeem Ghali, Hussain Alizadeh, Sebastian Brandner, Csaba Bödör, Béla Kajtár, Donát Alpár, Ákos Nagy, András Matolcsy, Irén Csala, Hajnalka Rajnai, Tamás Schneider, Adrienn Burján, James Storhoff, Lilla Reiniger
Publikováno v:
Journal of Neuropathology & Experimental Neurology
Primary central nervous system lymphomas (PCNSL) are aggressive non-Hodgkin lymphomas affecting the central nervous system (CNS). Although immunophenotyping studies suggested an uniform activated B-cell (ABC) origin, more recently a spectrum of ABC a
Autor:
É. Karádi, Á. Kellner, Hajnalka Andrikovics, Dóra Marosvári, Miklos Egyed, Péter Rajnics, M. Moizs, Cs. Bödör, Péter Attila Király
Publikováno v:
Leukemia Research. 48:101-106
The aim of our study was to evaluate the possible effect of lipocalin 2 on thrombotic events in polycythemia vera and essential thrombocythemia patients. The samples of 89 patients were collected and RNA based method was used to evaluate the relative
Autor:
Péter Attila Király, Judit Csomor, Krisztián Kállay, Dóra Marosvári, Csaba Bödör, Gábor Benyó, Anita Szőke
Publikováno v:
Orvosi Hetilap. 157:283-289
Myelodysplastic syndrome and acute myeloid leukaemia are mainly sporadic diseases, however, rare familial cases exist. These disorders are considered rare, but are likely to be more common than currently appreciated, and are characterized by the auto
Autor:
Violetta Piurkó, Irén Csala, Dóra Marosvári, András Matolcsy, Csaba Bödör, Katalin Dezső, Hajnalka Rajnai, Lilla Reiniger, Kinga Szurián
Publikováno v:
Experimental and molecular pathology. 105(2)
Lymph node involvement of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) is characterised by the diffuse infiltration of small neoplastic lymphocytes, which is accompanied by the presence of proliferation centres (PCs) comprising
Autor:
Viktória, Fésüs, Dóra, Marosvári, Béla, Kajtár, Péter Attila, Király, Judit, Demeter, Tímea, Gurbity Pálfi, Miklós, Egyed, Márk, Plander, Péter, Farkas, Zoltán, Mátrai, András, Matolcsy, Csaba, Bödör
Publikováno v:
Orvosi hetilap. 158(6)
In recent years much progress has been made in the therapy of chronic lymphocytic leukaemia, as the new innovative medicine proved to be effective in managing patients carrying TP53 abnormalities. To identify all these patients, it is essential to sc
Autor:
Richárd, Kiss, Attila Péter, Király, Júlia, Gaál-Weisinger, Dóra, Marosvári, Péter Ambrus, Gángó, Judit, Demeter, Csaba, Bödör
Publikováno v:
Magyar onkologia. 61(1)
The last fifteen years brought a revolution both in treatment and diagnostics of chronic myeloid leukemia. Nowadays, the main method for monitoring of the disease is molecular monitoring with real-time PCR technology which can indicate treatment modi
Autor:
Szabolcs Tasnády, Csaba Bödör, Attila Gyenesei, Donát Alpár, Péter Farkas, Dóra Marosvári, Dóra Aczél, András Matolcsy, Viktória Fésüs, Marienn Réti, Lilla Reiniger, Richárd Kiss, Emma Ádám, Noémi Nagy, Bence Galik, Ambrus Gángó, András Kozma, Zoltán Mátrai, Ákos Nagy, Szilvia Krizsán
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:S279
Introduction: The irreversible Bruton tyrosine kinase (BTK) inhibitor ibrutinib is changing the paradigm of the treatment of chronic lymphocytic leukemia (CLL) with remarkable outcomes in first line as well as in relapsed CLL, including high risk pat